Ladiratuzumab vedotin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Ladiratuzumab vedotin
DrugBank Accession Number
DB15409
Background

Ladiratuzumab vedotin is under investigation in clinical trial NCT01969643 (A Safety Study of SGN-LIV1A in Breast Cancer Patients).

Type
Biotech
Groups
Investigational
Synonyms
  • Ladiratuzumab vedotin
  • SGN-LIV1A

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Ladiratuzumab vedotin.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Ladiratuzumab vedotin.
AducanumabThe risk or severity of adverse effects can be increased when Aducanumab is combined with Ladiratuzumab vedotin.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ladiratuzumab vedotin.
AlirocumabThe risk or severity of adverse effects can be increased when Alirocumab is combined with Ladiratuzumab vedotin.
AmivantamabThe risk or severity of adverse effects can be increased when Ladiratuzumab vedotin is combined with Amivantamab.
AnifrolumabThe risk or severity of adverse effects can be increased when Anifrolumab is combined with Ladiratuzumab vedotin.
AnsuvimabThe risk or severity of adverse effects can be increased when Ladiratuzumab vedotin is combined with Ansuvimab.
Anthrax immune globulin humanThe risk or severity of adverse effects can be increased when Anthrax immune globulin human is combined with Ladiratuzumab vedotin.
Antilymphocyte immunoglobulin (horse)The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Ladiratuzumab vedotin.
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
VM4G5D1A60
CAS number
1629760-29-7

References

General References
Not Available
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2RecruitingTreatmentAdenocarcinoma of the Stomach / Adenocarcinomas of the Gastroesophageal Junction / Esophageal Squamous Cell Carcinoma (ESCC) / Malignant Melanoma of Skin / Non Small Cell Lung Cancer Squamous (NSCLC-Sq) / Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC) / Prostate Cancer / Small Cell Lung Cancer (SCLC) / Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)1
2RecruitingTreatmentBreast Cancer / Breast Cancer (Triple Negative Breast Cancer (TNBC)) / Early Breast Cancer / Hemangiosarcoma / HER 2 Negative Breast Cancer / HER2/Neu-positive Breast Cancer / Hormone Receptor Negative Tumor / Hormone Receptor Positive Tumor / Locally Advanced Breast Cancer (LABC) / Neoplasms, Breast / Tumors, Breast1
1RecruitingTreatmentBreast Cancer1
1, 2RecruitingTreatmentBreast Cancer (Triple Negative Breast Cancer (TNBC))1
1, 2RecruitingTreatmentNeoplasms, Breast1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on May 20, 2019 15:26 / Updated on February 21, 2021 18:55